RS1 Antibody

What is RS1 protein and what is its role in retinal biology?

RS1 (Retinoschisin) is a protein encoded by the RS1 gene that plays critical roles in maintaining retinal integrity. It binds negatively charged membrane lipids, such as phosphatidylserine and phosphoinositides, and contributes to cell-cell adhesion processes in the retina through homomeric interactions between octamers present on neighboring cell surfaces . This protein is required for normal structural organization and function of the retina .

The absence or dysfunction of RS1 protein results in X-linked retinoschisis (XLRS), a condition characterized by retinal cavities (schisis), synaptic dysfunction, reduced visual acuity, and increased susceptibility to retinal detachment . RS1 is primarily secreted in the outer retina, making it a crucial marker for retinal research .

What applications are RS1 antibodies validated for in research?

RS1 antibodies have been validated for multiple research applications, providing flexibility in experimental design:

• Western Blotting (WB): Detects RS1 protein in tissue lysates, showing a characteristic band at approximately 25 kDa

• Immunohistochemistry: Both on paraffin-embedded (IHC-P) and frozen sections (IHC-Fr)

• Immunocytochemistry/Immunofluorescence (ICC/IF): For cellular localization studies

• Immunoprecipitation (IP): For isolating RS1 and associated protein complexes

Experimental data confirms that RS1 antibodies like ab314231 work effectively across these applications with mouse, rat, and human samples .

For Western Blotting:

• Use 20 μg of retinal tissue lysate per lane

• Dilute primary antibody to 1/1000

• Use HRP-conjugated secondary antibody at 1/100000 dilution

• Expected result: Band at approximately 25 kDa

For Immunohistochemistry (Paraffin):

• Perform heat-mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 10 minutes

• Dilute antibody to 1/10000 (0.052 μg/ml)

• Incubate for 10 minutes at room temperature

• Use polymer-based detection system

• Apply 3% hydrogen peroxide for 10 minutes after secondary antibody to reduce background

For Immunofluorescence:

• Fix tissues/cells with 4% paraformaldehyde

• Permeabilize with 0.1-0.2% TritonX-100

• Use antibody dilutions between 1/50-1/1000 depending on sample type

• Apply fluorophore-conjugated secondary antibody at 1/1000

• Counterstain nuclei with DAPI

For Immunoprecipitation:

• Use 2 μg antibody per 0.35 mg of tissue lysate (approximately 1/30 dilution)

• Detect with the same antibody at 1/1000 dilution via Western blot

• Use specialized secondary antibody for IP detection at 1/5000 dilution

What tissues and species demonstrate RS1 expression?

RS1 expression shows a distinctive tissue and species profile that researchers should consider:

• Tissue specificity: RS1 is predominantly expressed in the retina, with negative staining observed in other tissues such as kidney

• Species reactivity: Confirmed positive reactivity in human, mouse, and rat retinal tissues

• Cellular localization: Within the retina, RS1 localizes primarily to photoreceptor cells and is secreted into the extracellular space

This restricted expression pattern makes RS1 antibodies particularly valuable for retina-specific research and as a marker for retinal layers in structural studies.

What controls should be included in RS1 antibody experiments?

Robust controls are essential for reliable interpretation of RS1 antibody experiments:

• Positive control: Use retinal tissue lysates or sections known to express RS1

• Negative control: Include non-retinal tissues such as kidney where RS1 is not expressed

• Method-specific controls:

  • For IP: Include isotype control antibody (e.g., rabbit monoclonal IgG) processed identically

  • For IHC/IF: Include secondary-antibody-only controls

  • For WB: Include molecular weight markers to confirm band size (25 kDa)

These controls help distinguish specific RS1 signals from background or non-specific reactions, ensuring experimental validity.

How can RS1 antibodies be used to study X-linked retinoschisis (XLRS)?

RS1 antibodies provide powerful tools for studying XLRS through several approaches:

Disease Mechanism Studies:

• Analyze RS1 protein expression and localization in affected versus normal tissues

• Assess protein-protein interactions through co-immunoprecipitation

• Evaluate structural consequences of RS1 mutations

Gene Therapy Assessment:

In gene therapy for XLRS (as described in search result ), RS1 antibodies are crucial for:

The clinical trial described in search result specifically monitored patients for development of anti-RS1 antibodies following AAV8-RS1 gene therapy . Importantly, none of the participants demonstrated a humoral antibody response to the RS1 protein at any time point following vector dosing .

What are the key considerations for quantitative analysis using RS1 antibodies?

For accurate quantitative analysis of RS1 expression:

Sample Preparation Standardization:

• Use consistent tissue collection, fixation, and processing protocols

• Standardize protein extraction methods for all samples

• Maintain identical antibody concentrations and incubation times

Western Blot Quantification:

• Include appropriate loading controls

• Perform densitometry using calibrated software

• Generate standard curves using recombinant RS1 if absolute quantification is needed

Image Analysis Parameters:

• Maintain consistent acquisition settings (exposure time, gain)

• Apply threshold-based analysis for signal quantification

• Use z-stack imaging for three-dimensional samples

Replication and Statistical Analysis:

• Include sufficient biological replicates (minimum n=3)

• Apply appropriate statistical tests based on data distribution

• Report confidence intervals and significance values

How can RS1 antibodies be combined with other markers in multiplexed studies?

Combining RS1 antibodies with other markers provides valuable context for understanding RS1 function:

Co-localization Protocol Example:

As demonstrated in search result , successful co-staining can be achieved with:

• RS1 rabbit antibody (1/50 dilution) + Alexa Fluor 488 anti-rabbit secondary

• MAP2 mouse antibody (1/500 dilution) + Alexa Fluor 594 anti-mouse secondary

• DAPI nuclear counterstain

Recommended Marker Combinations:

• Cell type identification: Pair with photoreceptor, bipolar cell, or Müller cell markers

• Subcellular localization: Combine with markers for specific cellular compartments

• Functional associations: Co-stain with synaptic proteins or cell adhesion molecules

Technical Considerations:

• Select antibodies raised in different host species to avoid cross-reactivity

• Optimize antibody concentrations to achieve balanced signal intensities

• Use confocal microscopy for precise co-localization analysis

• Implement appropriate spectral separation for fluorophore combinations

Weak or No Signal:

• Verify sample origin (remember RS1 is retina-specific)

• Optimize antibody concentration (try a range from 1/50 to 1/10000 depending on application)

• For paraffin sections, test different antigen retrieval methods

• Increase protein loading for Western blots

• Extend primary antibody incubation time

High Background:

• Increase blocking time/concentration

• Implement hydrogen peroxide treatment (3% for 10 minutes) after secondary antibody

• Add additional washing steps with higher detergent concentration

• Reduce primary and secondary antibody concentrations

• Use more specific detection systems

Multiple Bands in Western Blot:

• Include protease inhibitors in lysis buffer

• Reduce sample heating time/temperature to prevent aggregation

• Verify expected molecular weight (25 kDa for RS1)

• Test antibody specificity using appropriate controls

How are RS1 antibodies used in gene therapy research for XLRS?

RS1 antibodies play a crucial role in evaluating gene therapy approaches for XLRS:

Monitoring Therapeutic Efficacy:

• Detect restoration of RS1 expression in treated retinal areas

• Assess proper localization of the expressed protein

• Correlate protein expression with functional improvements

Immune Response Evaluation:

The clinical trial data in search result shows that monitoring anti-RS1 antibody development is essential for safety assessment. The study revealed:

Importantly, none of the participants developed detectable anti-RS1 antibodies following gene therapy, even when some developed anti-AAV8 capsid antibodies .

Protocol Considerations:

• Use sensitive detection methods to distinguish therapeutic RS1 from endogenous protein

• Implement longitudinal sampling to track expression over time

• Compare treated versus untreated regions within the same eye when possible

• Correlate antibody findings with clinical outcomes